A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

Key facts

Sponsor

BioMarin Pharmaceutical

Principal Investigator

Debra Lounsbury

BioMarin Pharmaceutical

Intervention

BMN 165 (rAvPAL-PEG)(biological)

Enrollment

24 enrolled

Eligibility

16-70 years · All sexes

Timeline

2012 – 2015

Study locations (6)

• The Children's Hospital, Aurora, Colorado, United States
• University of Florida, Gainesville, Gainesville, Florida, United States
• Children's Hospital Boston, Boston, Massachusetts, United States
• Nebraska Medical Center, Omaha, Nebraska, United States
• Albany Medical Center, Albany, New York, United States
• University of Utah Hospital, Salt Lake City, Utah, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic phenylketonuria

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07241234
  A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
  Agios Pharmaceuticals, Inc.
• RECRUITINGNANCT07526909
  Effect of Different Meal Types Given Before Exercise on Plasma Amino Acid Levels and Metabolic Control Parameters in Classical Phenylketonuria Patients Undergoing Aerobic and Resistance Exercises
  Hacettepe University
• ACTIVE NOT RECRUITINGPHASE4NCT06780332
  Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
  BioMarin Pharmaceutical
• RECRUITINGNANCT01659749
  Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria
  Emory University

See all trials for Classic phenylketonuria →